Cogent Biosciences, Inc. (COGT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$34.76-0.54%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · COGT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -33.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
COGT — debt issuance
Dated 2026-08-10
Other Events. As previously disclosed, on May 6, 2022, Cogent Biosciences, Inc. (the “Company”) entered into a Sales Agreement with Guggenheim Securities, LLC (“Guggenheim Securities”), as amended by that certain Amendment No. 1 to Sales Agreement, dated November 7, 2025 (as amended, the “Sales Agreement”), pursuant to which the Company may offer and sell shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), at any time and from time to time through or to Guggenhe…
Why it matters: Funding is important for keeping operations running. It also helps launch new products.
Supportive ifManagement shares news of a successful funding round or a new partnership.
Worry ifThere are no updates on funding or news about financial troubles.
Why it matters: Funding is crucial for Cogent to continue operations and support growth.
Supportive ifA funding deal or partnership that keeps operations going until 2028.
Worry ifNo funding updates or indications of cash flow issues.
Why it matters: A drop in sector revenue growth could show bigger problems for Cogent.
Worry ifSector revenue growth reports show a drop below the median growth rate.
Less concerning ifSector revenue growth stays steady or goes up, which helps Cogent's outlook.
Why it matters: Completing dose escalation is important for moving the pipeline forward. It shows progress in making new treatments.
Supportive ifCogent says it has finished dose escalation for CGT4255.
Worry ifCogent delays or fails to complete dose escalation for CGT4255.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$154 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $464 loss on $10,000 · 4.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,634 loss on $10,000 · 26.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This data will show how well bezuclastinib works for GIST patients. Positive results could boost confidence in the drug's potential.
Supportive ifThe presentation on May 30 shows positive results from the Phase 3 PEAK trial.
Worry ifThe presentation shows poor results or no important findings from the trial.
Why it matters: If healthcare revenue growth speeds up, it could benefit Cogent's outlook.
Supportive ifHealthcare revenue growth exceeds 10% year over year.
Worry ifHealthcare revenue growth remains below 10% year over year.
Why it matters: Approval would mark a key milestone for Cogent and validate its pipeline strategy. It could drive revenue growth and investor confidence.
Supportive ifFDA grants approval for bezuclastinib for GIST by the PDUFA date.
Worry ifThe FDA denies approval. They may delay the decision past November 30, 2026.
Why it matters: Updates on cash runway will tell investors if the company can fund its work.
Watch forQ2 earnings report shows cash is enough to fund operations until 2028.
Also watch forQ2 earnings report shows cash runway is shorter than expected.
Why it matters: Finishing enrollment is important for quick results. It may affect future growth.
Supportive ifCogent announces it has finished enrollment in the SUMMIT trial.
Worry ifEnrollment remains incomplete past the end of 2026.
Why it matters: Approval would help Cogent grow in the market for rare diseases.
Supportive ifThe FDA approves bezuclastinib for NonAdvSM by the PDUFA date.
Worry ifThe FDA denies approval. They may delay the decision past December 30, 2026.
Why it matters: Submitting the NDA is key for expanding bezuclastinib's market potential. This could lead to more revenue.
Supportive ifNDA for bezuclastinib in AdvSM is submitted in the first half of 2026.
Worry ifThe NDA submission is delayed or not completed as planned.
Why it matters: The launch is crucial for generating revenue. A successful launch could improve the company's financial outlook.
Supportive ifBezuclastinib launches as planned in the second half of 2026.
Worry ifThe launch is delayed or stopped because of regulatory problems.
Why it matters: These submissions show Cogent is making progress in growing their pipeline.
Supportive ifCogent submits IND applications for CGT1815 and CGT1145 by the end of 2026.
Worry ifCogent fails to submit IND applications for CGT1815 and CGT1145 by the end of 2026.